{
    "id": 26978,
    "fullName": "RAD51D G258Sfs*50",
    "impact": "frameshift",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RAD51D G258Sfs*50 indicates a shift in the reading frame starting at amino acid 258 and terminating 50 residues downstream causing a premature truncation of the 328 amino acid Rad51d protein (UniProt.org). G258Sfs*50 has been identified in the scientific literature (PMID: 28588062), but has not been biochemically characterized and therefore, its effect on Rad51d protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 9883,
                    "pubMedId": 28588062,
                    "title": "Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588062"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5892,
        "geneSymbol": "RAD51D",
        "terms": [
            "RAD51D",
            "BROVCA4",
            "R51H3",
            "RAD51L3",
            "TRAD"
        ]
    },
    "variant": "G258Sfs*50",
    "createDate": "09/08/2017",
    "updateDate": "10/09/2019",
    "referenceTranscriptCoordinates": {
        "id": 133694,
        "transcript": "NM_002878",
        "gDna": "chr17:g.(35101016_35101332)",
        "cDna": "c.(772_924)",
        "protein": "p.G258Sfs*50",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12049,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, an ovarian carcinoma patient harboring a RAD51D G258Sfs*50 germline mutation demonstrated stable disease when treated with Rubraca (rucaparib) (PMID: 28588062).",
            "molecularProfile": {
                "id": 28329,
                "profileName": "RAD51D G258Sfs*50"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9883,
                    "pubMedId": 28588062,
                    "title": "Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12050,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an ovarian carcinoma patient harboring a RAD51D G258Sfs*50 germline mutation developed resistance to Rubraca (rucaparib) after acquisition of RAD51D S257_R259delinsK (PMID: 28588062).",
            "molecularProfile": {
                "id": 28393,
                "profileName": "RAD51D S257_R259delinsK RAD51D G258Sfs*50"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9883,
                    "pubMedId": 28588062,
                    "title": "Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28329,
            "profileName": "RAD51D G258Sfs*50",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28393,
            "profileName": "RAD51D S257_R259delinsK RAD51D G258Sfs*50",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 133694,
            "transcript": "NM_002878",
            "gDna": "chr17:g.(35101016_35101332)",
            "cDna": "c.(772_924)",
            "protein": "p.G258Sfs*50",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}